The global pharmaceutical CDMO for formulations market size is calculated at USD 48.85 billion in 2025 and is forecasted to reach around USD 96.57 billion by 2034, accelerating at a CAGR of 7.90% from 2025 to 2034. The North America market size surpassed USD 19.28 billion in 2024 and is expanding at a CAGR of 7.69% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical CDMO for Formulations Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical CDMO for Formulations Market, by Dosage Form
8.1.1 Oral Solids
8.1.1.1. Market Revenue and Forecast
8.1.2. Oral Liquids
8.1.2.1. Market Revenue and Forecast
8.1.3. Injectables
8.1.3.1. Market Revenue and Forecast
8.1.4. Topicals
8.1.4.1. Market Revenue and Forecast
8.1.5. Inhalation Products
8.1.5.1. Market Revenue and Forecast
8.1.6. Transdermal And Patches
8.1.6.1. Market Revenue and Forecast
8.1.7. Others
8.1.7.1. Market Revenue and Forecast
9.1. Pharmaceutical CDMO for Formulations Market, by Therapeutic Area
9.1.1. Oncology
9.1.1.1. Market Revenue and Forecast
9.1.2. Cardiology
9.1.2.1. Market Revenue and Forecast
9.1.3. Central Nervous System
9.1.3.1. Market Revenue and Forecast
9.1.4. Gastroenterology
9.1.4.1. Market Revenue and Forecast
9.1.5. Infectious Diseases
9.1.5.1. Market Revenue and Forecast
9.1.6. Endocrinology (Diabetes, Hormonal Therapy)
9.1.6.1. Market Revenue and Forecast
10.1. Pharmaceutical CDMO for Formulations Market, by End User
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast
10.1.2. Biopharmaceutical Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Dosage Form
11.1.2. Market Revenue and Forecast, by Therapeutic Area
11.1.3. Market Revenue and Forecast, by End User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Dosage Form
11.1.4.2. Market Revenue and Forecast, by Therapeutic Area
11.1.4.3. Market Revenue and Forecast, by End User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Dosage Form
11.1.5.2. Market Revenue and Forecast, by Therapeutic Area
11.1.5.3. Market Revenue and Forecast, by End User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Dosage Form
11.2.2. Market Revenue and Forecast, by Therapeutic Area
11.2.3. Market Revenue and Forecast, by End User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Dosage Form
11.2.4.2. Market Revenue and Forecast, by Therapeutic Area
11.2.4.3. Market Revenue and Forecast, by End User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Dosage Form
11.2.5.2. Market Revenue and Forecast, by Therapeutic Area
11.2.5.3. Market Revenue and Forecast, by End User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Dosage Form
11.2.6.2. Market Revenue and Forecast, by Therapeutic Area
11.2.6.3. Market Revenue and Forecast, by End User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Dosage Form
11.2.7.2. Market Revenue and Forecast, by Therapeutic Area
11.2.7.3. Market Revenue and Forecast, by End User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Dosage Form
11.3.2. Market Revenue and Forecast, by Therapeutic Area
11.3.3. Market Revenue and Forecast, by End User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Dosage Form
11.3.4.2. Market Revenue and Forecast, by Therapeutic Area
11.3.4.3. Market Revenue and Forecast, by End User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Dosage Form
11.3.5.2. Market Revenue and Forecast, by Therapeutic Area
11.3.5.3. Market Revenue and Forecast, by End User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Dosage Form
11.3.6.2. Market Revenue and Forecast, by Therapeutic Area
11.3.6.3. Market Revenue and Forecast, by End User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Dosage Form
11.3.7.2. Market Revenue and Forecast, by Therapeutic Area
11.3.7.3. Market Revenue and Forecast, by End User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Dosage Form
11.4.2. Market Revenue and Forecast, by Therapeutic Area
11.4.3. Market Revenue and Forecast, by End User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Dosage Form
11.4.4.2. Market Revenue and Forecast, by Therapeutic Area
11.4.4.3. Market Revenue and Forecast, by End User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Dosage Form
11.4.5.2. Market Revenue and Forecast, by Therapeutic Area
11.4.5.3. Market Revenue and Forecast, by End User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Dosage Form
11.4.6.2. Market Revenue and Forecast, by Therapeutic Area
11.4.6.3. Market Revenue and Forecast, by End User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Dosage Form
11.4.7.2. Market Revenue and Forecast, by Therapeutic Area
11.4.7.3. Market Revenue and Forecast, by End User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Dosage Form
11.5.2. Market Revenue and Forecast, by Therapeutic Area
11.5.3. Market Revenue and Forecast, by End User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Dosage Form
11.5.4.2. Market Revenue and Forecast, by Therapeutic Area
11.5.4.3. Market Revenue and Forecast, by End User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Dosage Form
11.5.5.2. Market Revenue and Forecast, by Therapeutic Area
11.5.5.3. Market Revenue and Forecast, by End User
12.1. Lonza
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Thermo Fisher Scientific, Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Recipharm AB
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Laboratory Corporation of America Holdings (LabCorp)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Catalent, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. WuXi AppTec, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Piramal Pharma Solutions
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Siegfried Holding AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. CordenPharma International
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Cambrex Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample